TASK ORDER: PREVENTING LUNG CANCER BY TARGETING ACTIVATED STAT3
任务顺序:通过针对激活的 STAT3 来预防肺癌
基本信息
- 批准号:10269147
- 负责人:
- 金额:$ 77.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2023-03-20
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisBase PairingBindingBiological MarkersButanonesCause of DeathCell ProliferationChemopreventionChronicChronic Obstructive Airway DiseaseFamilyFutureGenesImmune responseInflammationInhalationMalignant NeoplasmsMalignant neoplasm of lungMethodsMolecularMolecular AbnormalityMusNon-Small-Cell Lung CarcinomaNormal CellOligonucleotidesPeriodicityPreventivePreventive InterventionPulmonary EmphysemaResearchResponse ElementsRiskSTAT3 geneSmokerStat3 proteinTobacco-Associated CarcinogenTobacco-Related CarcinomaTravelUnited Statescancer riskcancer typedimerdosagelung cancer preventionmemberpreventpromotertobacco exposuretranscription factor
项目摘要
Lung cancer remains the number one cause of death from cancer in the United States. Ex-smokers in particular have an elevated lung cancer risk due to the presence of persistent genetic abnormalities in their airways and chronic inflammation from COPD/emphysema induced by previous tobacco exposure. Chemoprevention is an obvious avenue for reducing future cancer for this at-risk group, but safe and efficacious agents are currently lacking.
Signal transducer and activator of transcription 3 (STAT3) is one of the seven members of a family of transcription factors that regulates cell proliferation, differentiation, apoptosis, and the immune response. Although the activation of STAT3 is transient and highly regulated in normal cells, it is constitutively active in several types of cancer, including lung cancer. Recent findings suggest that targeting activated STAT3 with a cyclic STAT3 decoy (CS3D) could be a successful preventive intervention in non-small cell lung cancer as well as other tobacco-related cancers.
CS3D, developed by Dr. Jennifer Grandis and colleagues, is a circularized double-stranded oligonucleotide containing a 15 base-pair sequence corresponding to the STAT3 response element of the STAT3 target genes. CS3D interacts with STAT3 dimers, acting as a molecular sink to competitively inhibit binding of the dimer to the promoters of STAT3 target genes and inducing p-STAT3 proteasomal degradation. CS3D is non-toxic, thermally stable, and remains active after systemic administration. The purpose of this Task Order is to evaluate CS3D for the prevention of lung cancer in mice exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
肺癌仍然是美国癌症死亡的头号原因。前吸烟者患肺癌的风险尤其高,这是因为他们的呼吸道存在持续性的遗传异常,以及以前接触烟草导致的慢性阻塞性肺病/肺气肿引起的慢性炎症。对于这一高危人群来说,化学预防是减少未来癌症的明显途径,但目前缺乏安全有效的药物。
信号转导和转录激活因子3(STAT3)是调控细胞增殖、分化、凋亡和免疫反应的转录因子家族的7个成员之一。尽管STAT3的激活在正常细胞中是短暂的,并且受到高度调控,但它在包括肺癌在内的几种类型的癌症中都是结构性活跃的。最近的研究结果表明,靶向激活的STAT3与环状STAT3诱饵(CS3D)可能是一种成功的预防干预非小细胞肺癌以及其他烟草相关的癌症。
CS3D由詹妮弗·格兰迪斯博士及其同事开发,是一种环状双链寡核苷酸,包含与STAT3靶基因的STAT3反应元件相对应的15个碱基对序列。CS3D与STAT3二聚体相互作用,竞争性地抑制二聚体与STAT3靶基因启动子的结合,诱导p-STAT3蛋白酶体降解。CS3D无毒,热稳定,全身给药后仍保持活性。本任务单的目的是评估CS3D对暴露于烟草致癌物4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone(NNK)的小鼠肺癌的预防作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGIE CLAPPER其他文献
MARGIE CLAPPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGIE CLAPPER', 18)}}的其他基金
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
基本标题:预防临床前药物开发计划:临床前疗效和中间终点 BIOMAKERSTASK 订单标题:再次疫苗
- 批准号:
10651935 - 财政年份:2022
- 资助金额:
$ 77.99万 - 项目类别:
TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTIONPREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFF
任务单标题:微生物代谢物拟态,一种预防结肠癌的纳米药物预防临床前药物开发计划:临床前 EFF
- 批准号:
10706658 - 财政年份:2022
- 资助金额:
$ 77.99万 - 项目类别:
TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
任务单标题:用于预防结肠炎相关结直肠癌的下一代 GP130/IL-6/STAT3 抑制剂
- 批准号:
10627413 - 财政年份:2022
- 资助金额:
$ 77.99万 - 项目类别:
HHSN2612012000151/HHSN2610006Base Contract Title: Preclinical Efficacy and Intermediate Biomarkers. Task Order Title: Modulation of miRNA Expression in Blood or Other Biological Fluids Compared wi
HHSN2612012000151/HHSN2610006基本合同标题:临床前功效和中间生物标志物。
- 批准号:
8947461 - 财政年份:2014
- 资助金额:
$ 77.99万 - 项目类别:
PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ASSAYS
临床前疗效和中间生物标志物测定
- 批准号:
7543325 - 财政年份:2004
- 资助金额:
$ 77.99万 - 项目类别:
PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND
中间终点的临床前评估和
- 批准号:
3617865 - 财政年份:1992
- 资助金额:
$ 77.99万 - 项目类别:
PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND
中间终点的临床前评估和
- 批准号:
3617866 - 财政年份:1992
- 资助金额:
$ 77.99万 - 项目类别:
相似海外基金
Mapping long-range G-G base pairing interaction within the human genome
绘制人类基因组内长程 G-G 碱基配对相互作用图谱
- 批准号:
2887243 - 财政年份:2023
- 资助金额:
$ 77.99万 - 项目类别:
Studentship
Structure and function of DNA polymerase lambda opposite DNA lesions which disrupt Watson-Crick base pairing
DNA 聚合酶 lambda 的结构和功能与破坏 Watson-Crick 碱基配对的 DNA 损伤相反
- 批准号:
10065004 - 财政年份:2017
- 资助金额:
$ 77.99万 - 项目类别:
Molecular basis of acceleration of base-pairing between sRNA and target mRNA by Hfq
Hfq加速sRNA与靶mRNA碱基配对的分子基础
- 批准号:
16K07259 - 财政年份:2016
- 资助金额:
$ 77.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating mRNA-rRNA base pairing in translation initiation
研究翻译起始中的 mRNA-rRNA 碱基配对
- 批准号:
9171027 - 财政年份:2016
- 资助金额:
$ 77.99万 - 项目类别:
Expanding the natural DNA base-pairing alphabet: Small molecule mediated assembly of DNA nanomaterials with novel geometries
扩展天然 DNA 碱基配对字母表:小分子介导的具有新颖几何形状的 DNA 纳米材料的组装
- 批准号:
444512-2013 - 财政年份:2015
- 资助金额:
$ 77.99万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Expanding the natural DNA base-pairing alphabet: Small molecule mediated assembly of DNA nanomaterials with novel geometries
扩展天然 DNA 碱基配对字母表:小分子介导的具有新颖几何形状的 DNA 纳米材料的组装
- 批准号:
444512-2013 - 财政年份:2014
- 资助金额:
$ 77.99万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Expanding the natural DNA base-pairing alphabet: Small molecule mediated assembly of DNA nanomaterials with novel geometries
扩展天然 DNA 碱基配对字母表:小分子介导的具有新颖几何形状的 DNA 纳米材料的组装
- 批准号:
444512-2013 - 财政年份:2013
- 资助金额:
$ 77.99万 - 项目类别:
Postgraduate Scholarships - Doctoral
Effects of Vicinal Surface Chemistry on DNA Base-Pairing using Single-Molecule RE
使用单分子 RE 邻位表面化学对 DNA 碱基配对的影响
- 批准号:
8280932 - 财政年份:2012
- 资助金额:
$ 77.99万 - 项目类别:
Effects of Vicinal Surface Chemistry on DNA Base-Pairing using Single-Molecule RE
使用单分子 RE 邻位表面化学对 DNA 碱基配对的影响
- 批准号:
8442838 - 财政年份:2012
- 资助金额:
$ 77.99万 - 项目类别:
COLLABORATIVE RESEARCH: Uncovering the Kinetic Mechanism of Base-Pairing and Stacking in RNA Folding
合作研究:揭示 RNA 折叠中碱基配对和堆积的动力学机制
- 批准号:
0920588 - 财政年份:2009
- 资助金额:
$ 77.99万 - 项目类别:
Continuing Grant